Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Bristol-Myers Squibb
National Cancer Institute (NCI)
BicycleTx Limited
AbbVie
Bristol-Myers Squibb
All India Institute of Medical Sciences
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Bristol-Myers Squibb
NRG Oncology
NRG Oncology
Eastern Cooperative Oncology Group
Daiichi Sankyo
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Hoffmann-La Roche
AbbVie
Hoffmann-La Roche
Eikon Therapeutics
Regeneron Pharmaceuticals
Shanghai JMT-Bio Inc.
Alliance for Clinical Trials in Oncology
University Health Network, Toronto
Universitätsklinikum Hamburg-Eppendorf
Karyopharm Therapeutics Inc
Fudan University
Privo Technologies